
|Videos|September 1, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Advertisement
Articles in this issue
over 8 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCover 8 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































